AngioLab, Inc. Logo

AngioLab, Inc.

Develops anti-angiogenic therapeutics and foods for angiogenesis-related diseases.

251280 | KO

Overview

Corporate Details

ISIN(s):
KR7251280004
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노3로 65, 대전광역시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

AngioLab, Inc. is a biotechnology company established in 1999 that specializes in the research and development of therapeutics based on angiogenesis inhibition. The company develops pharmaceuticals and health functional foods designed to treat a variety of angiogenesis-related diseases. Its core technology focuses on the discovery and application of anti-angiogenic and matrix metalloproteinase (MMP) inhibitors. AngioLab manages a pipeline of drug candidates, advancing them through clinical trials to create novel treatments for conditions driven by abnormal blood vessel formation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 63.7 KB
2025-09-10 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.7 KB
2025-07-17 00:00
Share Issue/Capital Change
기타주요경영사항(자율공시) (전환우선주의 보통주 전환)
Korean 7.8 KB
2025-04-23 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.7 KB
2025-04-08 00:00
Share Issue/Capital Change
기타주요경영사항(자율공시) (전환우선주의 보통주 전환)
Korean 7.8 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.8 KB
2025-03-20 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.9 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 9.6 KB
2025-03-18 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 342.5 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 261.5 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.8 KB
2025-03-07 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 19.9 KB
2025-03-07 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 18.7 KB
2025-03-04 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 42.6 KB
2025-02-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.1 KB

Automate Your Workflow. Get a real-time feed of all AngioLab, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AngioLab, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AngioLab, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

H.I.S. Co., Ltd. Logo
A major Japanese travel agency providing global tour packages, lodging, and transport.
Japan
9603
Hit Co., Ltd. Logo
Specialized OOH advertising firm providing digital & static billboards in high-visibility areas.
Japan
378A
HLB Therapeutics Co.,Ltd. Logo
Develops innovative drugs for rare eye diseases and brain tumors, with vaccine logistics.
South Korea
115450
HONYAKU Center Inc. Logo
Provides industrial translation and interpreting for patent, legal, and corporate clients.
Japan
2483
A holding company for advanced materials, AI/data solutions, mobility, and global logistics.
South Korea
487570
Human Metabolome Technologies, Inc. Logo
A leader in metabolomics, providing CE-MS analysis to support R&D in biotech, pharma, and food.
Japan
6090
Hybrigenics SA Logo
R&D provider of molecular interaction analysis to accelerate drug discovery for life science sectors.
France
ALHYG
Korean CRO offering end-to-end clinical trial services for pharma & bio ventures.
South Korea
187660
HYUNDAI BIOSCIENCE CO., LTD. Logo
Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.
South Korea
048410
iBio, Inc. Logo
AI-powered biotech developing antibody therapeutics for cardiometabolic diseases and obesity.
United States of America
IBIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.